Improvement in psoriasis after intradermal administration of heat‐killed Mycobacterium vaccae

Balagon, Maria V.; Walsh, Douglas S.; Tan, Paul; Cellona, Roland V.; Abalos, Rodolfo M.; Tan, Esterlina V.; Fajardo, T. T.; Watson, James D.; Walsh, G. P.

doi:10.1046/j.1365-4362.2000.00862.x

Cited by 22 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a recent review of the clinincal trials using M. vaccae for immunotherapy of tuberculosis see Stanford et al (2004). In addition, M. vaccae has been clinically tested for therapeutic effects with other diseases such as cancer, asthma, psoriasis, and atopic dermatitis (Hrouda et al 1998;Balagon et al 2000;O'Brien et al 2000;Arkwright and David 2001;Shirtcliffe et al 2001Shirtcliffe et al , 2003Hadley et al 2005).…”

Section: Introductionmentioning

confidence: 99%

The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production

Rodríguez-Güell

Agustí

Corominas

et al. 2006

Antonie Van Leeuwenhoek

View full text Add to dashboard Cite

Mycobacterium vaccae is of major pharmaceutical interest as an immunotherapeutic agent. Although M. vaccae 15483 ATCC(T) strain displays smooth and rough colonial morphologies on solid culture media, it is not known in which conditions M. vaccae switches from one colonial morphotype to the other or whether there are biological differences, especially immunological, between them. We have found that the change from a smooth to rough stable variant occurs spontaneously at 30 degrees C. The analysis of the composition of the cell wall in both variants showed that the smooth morphotype presents an extracellular material that has never previously been described and was identified as a long-chain saturated polyester that, interestingly, is not produced by the rough morphotype. Our results also indicate that this compound could be implicated in the spreading ability of smooth colonies. Proliferation, IFN-gamma and IL-12(p40) production by splenocyte cultures was significantly higher in mice immunised with the rough variant compared with those immunised with the smooth one. This latter finding suggests that the different colonial morphology of M. vaccae may affect the immunomodulatory effects induced from M. vaccae preparations.

show abstract

Section: Introductionmentioning

confidence: 99%

The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production

Rodríguez-Güell

Agustí

Corominas

et al. 2006

Antonie Van Leeuwenhoek

View full text Add to dashboard Cite

show abstract

“…A subsequent study supported its efficacy. [93] Balagon et al [94] tested psoriasis vaccine (PVAC) which is a more potent derivative of M. vaccae. It contains heat-killed, delipidated, deglycolipidated M. vaccae.…”

Section: Immunotherapymentioning

confidence: 99%

Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics?

Kanwar¹,

Yadav²,

Dogra³

2010

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Psoriasis is a common debilitating disease significantly affecting the quality of life of the patients. Majority of the psoriasis patients have mild disease which can be managed by topical therapies. Around 30% of the psoriasis patients require systemic therapy during the course of their disease. There is a vast array of drugs for the treatment. Methotrexate, cyclosporine and retinoids are the most commonly used conventional systemic drugs. Newer studies provide insight into their more effective and safer use and as combination therapy with biologics. In recent times, many new drugs with novel mechanisms of action other than biologics have been tried in psoriasis. In this article, we have reviewed the current developments and new found role of the conventional drugs as well as the newer nonbiologic systemic drugs in the treatment of psoriasis.

show abstract

“…As tetanus toxoid is now recognized as an adjuvant inducing variable Th1 to Th2 shift, 183 it is therefore not a truly inactive placebo 182 . In two other open‐label studies 24 Philippino patients received M. vaccae 184 and 20 a delipidated, deglycolipidated M. vaccae suspension 185 (DD‐MVAC or ‘PVAC’; developed to isolate the most active components of M. vaccae and with a 10‐fold lower dose of 50 µg vs. 500 µg 185 ), respectively, as two intradermal inoculations in lesion‐free deltoid skin separated by a period of 3 weeks. There was a marked improvement with 50% or more reduction in PASI in 58% of the PVAC‐treated group vs. 46% of the M. vaccae patients at 12 and 24 weeks, and improvements were about 3–4 weeks earlier for the PVAC‐treated patients 185 .…”

Section: Miscellaneousmentioning

confidence: 99%

Novel pharmacological approaches in the treatment of psoriasis

Schleyer

Landthaler

Szeimies

2004

Acad Dermatol Venereol

View full text Add to dashboard Cite

Progress in the understanding of psoriasis as a T-cell mediated inflammatory disease has led to the development of new immunomodulatory therapies. Currently the main focus is on the so-called biologics (or biological agents), including fusion proteins, monoclonal antibodies, cytokines and selective receptors. They mainly target single steps in the complex cascade of humoral and cellular inflammatory immuno-mechanisms that finally lead to the accelerated growth of epidermal and vascular cells in the psoriatic lesions. The most promising and advanced biological agents are discussed along with their influence on the critical pathophysiological steps in psoriasis, including depletion of T cells, blockade of initial T-cell activation and T-cell receptor (TCR) stimulation, blockade of costimulatory signals and T-cell proliferative signals as well as restoration of the T helper type 1 (Th1)/Th2 balance by diminishing type 1 cytokines and administration of type 2 cytokines. In addition to the biological agents, further development of 'classical' dermatological therapies, such as retinoids, or the discovery of new indications for non-dermatological agents contribute to the novel pharmacological approaches in the treatment of psoriasis.

show abstract

Improvement in psoriasis after intradermal administration of heat‐killed Mycobacterium vaccae

Abstract: Intradermal administration of heat-killed M. vaccae suspension was well tolerated and induced clinically significant improvement in a majority of psoriasis patients in this cohort. Placebo-controlled testing to further define the efficacy of this treatment is warranted.

Cited by 22 publications

References 40 publications

The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production

The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production

Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics?

Novel pharmacological approaches in the treatment of psoriasis

Contact Info

Product

Resources

About